SCHEMBL4699095

SCHEMBL4699095

O=c1[nH]cnn1Cc1ccccc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.51
PNP P00491 1/20 0.45
IDO1 P14902 1/20 0.45
F2 P00734 1/20 0.44
PLG P00747 1/20 0.44
ELANE P08246 1/20 0.44
CTSG P08311 1/20 0.44
CMA1 P23946 1/20 0.44
CTRC Q99895 1/20 0.44
RECQL P46063 1/20 0.43
NPC1 O15118 1/20 0.42
RAB9A P51151 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
CYP19A1 P11511 1/20 0.42
HSD17B10 Q99714 2/20 0.42
DAO P14920 1/20 0.42
ALDH1A1 P00352 2/20 0.41
GSK3A P49840 1/20 0.41
GSK3B P49841 1/20 0.41
MGLL Q99685 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18462113 0.82 ADORA2B (0.48) MAPTNPC1RAB9ASMN1; SMN2HSD17B10
SCHEMBL18462236 0.80 DAO (0.48) DAOALDH1A1GSK3AGSK3BMGLL
SCHEMBL437446 0.78 TDP1 (0.50) MAPTNPC1RAB9ASMN1; SMN2HSD17B10
SCHEMBL18462111 0.78 NPBWR1 (0.52) MAPTCMA1ALDH1A1GSK3AGSK3B
SCHEMBL31330349 0.77 GSK3A (0.50) MAPTDAOGSK3AGSK3BMGLL
SCHEMBL30020048 0.75 HSD17B10 (0.54) MAPTIDO1RECQLSMN1; SMN2HSD17B10
SCHEMBL15524645 0.73 MAPT (0.47) MAPTPNPRECQLHSD17B10ALDH1A1
SCHEMBL5905968 0.70 IDO1 (0.49) MAPTIDO1F2PLGELANE
SCHEMBL11288191 0.68 MAPT (1.00) MAPTPNPSMN1; SMN2HSD17B10ALDH1A1
SCHEMBL4182991 0.68 CYP19A1 (0.48) MAPTIDO1F2PLGELANE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025133078-A1 VIRAL PROTEASE INHIBITORS WITH A HYDROXYBENZYL ALCOHOL WARHEAD STICHTING RADBOUD UNIVERSITEIT (NL) 2025-06-26 WO disclosed
US-20180028660-A1 DRUG COMBINATIONS COMPRISING A DGAT INHIBITOR AND A PPAR-AGONIST JANSSEN PHARMACEUTICA NV (BE) 2018-02-01 US disclosed
US-9688696-B2 Piperidine/piperazine derivatives JANSSEN PHARMACEUTICA N.V. (BE) 2017-06-27 US disclosed
US-20170029440-A1 PIPERIDINE/PIPERAZINE DERIVATIVES JANSSEN PHARMACEUTICA NV (BE) 2017-02-02 US disclosed
EP-2616071-A2 FATTY ACID SYNTHASE INHIBITORS GlaxoSmithKline Intellectual Property Development Limited (GB) 2013-07-24 EP disclosed
WO-2012037299-A2 FATTY ACID SYNTHASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2012-03-22 WO disclosed
EP-0974587-B1 1-SUBSTITUTED 4-CARBAMOYL-1,2,4-TRIAZOL-5-ONE DERIVATIVES AND HERBICIDE HOKKO CHEM IND CO (JP) 2008-04-23 EP disclosed
US-6077814-A LOW PHYTOTOXICITY TO THE CROP PLANTS; SELECTIVE ACTIVITY HOKKO CHEMICAL INDUSTRY CO., LTD. (JP) 2000-06-20 US disclosed
EP-0974587-A1 1-SUBSTITUTED 4-CARBAMOYL-1,2,4-TRIAZOL-5-ONE DERIVATIVES AND HERBICIDE HOKKO CHEMICAL INDUSTRY CO. LTD. (JP) 2000-01-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170029440-A1 PIPERIDINE/PIPERAZINE DERIVATIVES DGAT1, PAOX, DGAT2 MAPT 2270/4885PNP 510/4885IDO1 1987/4885
US-20180028660-A1 DRUG COMBINATIONS COMPRISING A DGAT INHIBITOR AND A PPAR-AGONIST PPARG, PPARA, DGAT1 MAPT 2599/4885PNP 550/4885IDO1 3710/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.